医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Sinovac Amends Shareholder Rights Plan

2020年02月22日 AM06:15
このエントリーをはてなブックマークに追加


 

BEIJING

Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan. The amendment extends the expiration date of the plan from February 22, 2020 to February 22, 2021.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. Sinovac’s product portfolio includes vaccines against enterovirus71 (EV71), hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella vaccine and mumps. Healive, the hepatitis A vaccine manufactured by the Company, has passed the assessment under WHO prequalification procedures in 2017. The EV71 vaccine, an innovative vaccine developed by Sinovac against hand foot and mouth disease caused by EV71, was commercialized in China in 2016. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government’s vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. The Company is developing a number of new products including a Sabin-strain inactivated polio vaccine, pneumococcal polysaccharides vaccine, and a quadrivalent influenza vaccine. Sinovac primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The Company is registering its products in over 30 countries outside of China. For more information please see the Company’s website at www.sinovac.com.

Safe Harbor Statement

This announcement may include certain statements that are not descriptions of historical facts, but are forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. In particular, the outcome of any litigation is uncertain, and the Company cannot predict the potential results of the litigation it filed or that could be filed against it by others. Additionally, the triggering of a shareholder rights plan is nearly unprecedented, and the Company cannot predict the impact on the Company or its stock price should its rights plan have been triggered.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200221005463/en/

CONTACT

Sinovac Biotech Ltd.

Helen Yang

Tel: +86-10-8279-9871

Fax: +86-10-6296-6910

ir@sinovac.com

Media:

Abernathy MacGregor

Sheila Ennis +1-415-926-7961

sbe@abmac.com

Shawn Prince +1-212-371-5999

sip@abmac.com

Investors:

ICR Inc.

Bill Zima +1-646-308-1707

Email: william.zima@icrinc.com

MacKenzie Partners, Inc.

Paul Schulman +1-212-929-5364

pschulman@mackenziepartners.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • EsriがWHO加盟国にマッピング・リソースを提供
  • Seoul Viosys and SETi’s Violeds Technology Proves 99.9% Sterilization of Coronavirus (COVID-19) in 30 Seconds 
  • 武田ADCETRIS® (brentuximab vedotin)联合CHP(环磷酰胺、多柔比星和泼尼松)用于既往未曾治疗的全身性间变性大细胞淋巴瘤成人患者获得CHMP肯定意见
  • Esri将向WHO成员国提供测绘资源
  • SETi’s Violeds Technology Proves 99.9% Sterilization of Coronavirus (COVID-19) in 30 Seconds